Reversing Stage III Oral Adenocarcinoma in a Dog Treated with Anti-canine PD-1 Therapeutic Antibody: a Case Report

Overview

Journal Front Vet Sci

Specialty Veterinary Medicine

Date 2023 May 30

PMID 37252387

Authors

Shuo Xu

Jingshu Xie

Shuaiyu Wang

Na Tang

Junli Feng

Youhong Su

Gebin Li

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibody targeting programmed cell death-1 (PD-1) is one of the most promising treatment therapies for human cancers. Canine PD-1 antibodies used in clinical trials have also shown efficacy in treating canine cancers. An 11-year-old male intact border collie presented to us for evaluation of left cervical mass. Computed tomography (CT) examination revealed an irregular pharyngeal mass invading the surrounding soft tissue. Histological and immunohistochemical results were consistent with a diagnosis of adenocarcinoma, most likely originating from the minor salivary gland. An anti-canine PD-1 monoclonal antibody was administered. Two months after the initial treatment, the tumor reached partial remission and maintained as such for 6 months. Finally, the patient was euthanized due to reasons unrelated to cancer, with a survival time of 316 days. To our knowledge, this is the first report of response to PD-1 blockade treatment in canine adenocarcinoma.

Citing Articles

Leveraging single-cell transcriptomic data to uncover immune suppressive cancer cell subsets in triple-negative canine breast cancers.

Kim M, Borcherding N, Song W, Kolb R, Zhang W Front Vet Sci. 2024; 11:1434617.

PMID: 39376916 PMC: 11457229. DOI: 10.3389/fvets.2024.1434617.

An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1.

Sergent P, Pinto-Cardenas J, Carrillo A, Davalos D, Perez M, Lechuga D Cells. 2024; 13(17.

PMID: 39273048 PMC: 11394642. DOI: 10.3390/cells13171478.

References

Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y . Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. PLoS One. 2016; 11(6):e0157176. PMC: 4898770. DOI: 10.1371/journal.pone.0157176. View

Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K . PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021; 5(1):10. PMC: 7881100. DOI: 10.1038/s41698-021-00147-6. View

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S . Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. PLoS One. 2014; 9(6):e98415. PMC: 4051644. DOI: 10.1371/journal.pone.0098415. View

Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M . A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020; 10(1):18311. PMC: 7591904. DOI: 10.1038/s41598-020-75533-4. View

Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S . PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. Front Immunol. 2019; 10:1242. PMC: 6557993. DOI: 10.3389/fimmu.2019.01242. View

Cray M, Selmic L, Ruple A . Salivary neoplasia in dogs and cats: 1996-2017. Vet Med Sci. 2019; 6(3):259-264. PMC: 7397883. DOI: 10.1002/vms3.228. View

Baumeister S, Freeman G, Dranoff G, Sharpe A . Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016; 34:539-73. DOI: 10.1146/annurev-immunol-032414-112049. View

10.

Seifert G, BROCHERIOU C, Cardesa A, Eveson J . WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours. Pathol Res Pract. 1990; 186(5):555-81. DOI: 10.1016/S0344-0338(11)80220-7. View

11.

. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2017; 14(4):417-446. DOI: 10.1111/vco.283. View

12.

Hammer A, Getzy D, Ogilvie G, Upton M, Klausner J, Kisseberth W . Salivary gland neoplasia in the dog and cat: survival times and prognostic factors. J Am Anim Hosp Assoc. 2001; 37(5):478-82. DOI: 10.5326/15473317-37-5-478. View

13.

Coy J, Caldwell A, Chow L, Guth A, Dow S . PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet Comp Oncol. 2017; 15(4):1487-1502. DOI: 10.1111/vco.12294. View

14.

Chiou V, Burotto M . Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015; 33(31):3541-3. PMC: 4622096. DOI: 10.1200/JCO.2015.61.6870. View

15.

Shosu K, Sakurai M, Inoue K, Nakagawa T, Sakai H, Morimoto M . Programmed Cell Death Ligand 1 Expression in Canine Cancer. In Vivo. 2016; 30(3):195-204. View

16.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

17.

Li N, Wang G, Hou X, Tai R, Huang S, He Z . Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. Int Immunopharmacol. 2022; 108:108803. DOI: 10.1016/j.intimp.2022.108803. View

18.

Reckamp K . Real-World Pseudoprogression: an Uncommon Phenomenon. J Thorac Oncol. 2018; 13(7):880-882. DOI: 10.1016/j.jtho.2018.05.011. View

19.

Evans S, Thrall D . Postoperative orthovoltage radiation therapy of parotid salivary gland adenocarcinoma in three dogs. J Am Vet Med Assoc. 1983; 182(9):993-4. View

20.

Twomey J, Zhang B . Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021; 23(2):39. PMC: 7937597. DOI: 10.1208/s12248-021-00574-0. View